Risk of Recurrent Venous Thromboembolism and Mortality in Patients With Cancer Incidentally Diagnosed With Pulmonary Embolism: A Comparison With Symptomatic Patients On the basis of a nationwide MPN ...
CLN-049, a novel FLT3/CD3 bispecific T-cell engager, has received fast track designation from the FDA for the treatment of ...
Investigators from China used circulating tumor DNA testing alongside bone marrow assessments to evaluate patients' pretreatment and posttreatment disease levels and to track the course of the disease ...
Venclexta-based regimens showed survival benefits in AML and MDS, with a two-year overall survival rate of 46% and median survival of 18.73 months. Remission was achieved by 57.1% of AML patients and ...
Progress in the treatment of T-cell blood cancers – which are rare – has also been modest. So, much remains to be done to ...
Investigators say a better understanding of risk factors and categories can help personalize care for patients living with myelodysplastic syndrome (MDS). Men, patients with low absolute neutrophil ...
Outpatient hematopoietic stem cell transplantation following targeted antibody-based conditioning appeared safe and feasible among older patients with acute myeloid leukemia or myelodysplastic ...
Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. So, in terms of preventing MDS, that's a ...
The blood cancers acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are extremely challenging to treat. While advances in immunotherapy have cured many patients with other blood cancers, ...
AbbVie is stopping another early-phase clinical trial of anti-CD47 antibody lemzoparlimab. Weeks after pulling the plug on a multiple myeloma trial, the Big Pharma is halting a phase 1b trial that is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback